NERO trial: PARP inhibitors for chemosensitive NSCLC

Dr. Vokes on PARP Inhibitors for NSCLCПодробнее

Where can PARP inhibitors be usedПодробнее

2020 In Review: Olaparib & Rucaparib, FDA Approval | Ask a Prostate Expert, Mark Scholz, MDПодробнее

Dr. Simeone on Impact of PARP Inhibitors on Pancreatic CancerПодробнее

Dr. Vokes Discusses PARP Inhibitors in Lung CancerПодробнее

PARP Inhibitors: Assessing the Clinical Trial LandscapeПодробнее

PARP Inhibitor Trial UpdatesПодробнее

Distinguishing Between PARP Inhibitors in Breast CancerПодробнее

Expert report on survival data from pivotal trials with PARP inhibitors for BRCA-mut. Ovarian CancerПодробнее

SOLO-1 and PARP Inhibitors in Ovarian CancerПодробнее

NSCLC: Targeting PARP proteins and intracellular signaling componentsПодробнее

PARP Inhibition’s Role in Recurrent Ovarian CancerПодробнее

PARP inhibitors – a cancer drug discovery story | Professor Ruth Plummer FMedSciПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

PARP inhibitors: game-changers for ovarian cancer patients?Подробнее

PARP Inhibitors in Recurrent Ovarian CancerПодробнее

Assessing the role of PARP inhibitors and immunotherapy in ovarian cancerПодробнее

The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIAПодробнее

BRCA+ Pancreatic Cancer Maintenance Debate: PARP Inhibitor or Continued Chemo? - PARP InhibitorПодробнее